Back to Search
Start Over
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
- Source :
-
Clinical Immunology . May2015, Vol. 158 Issue 1, p1-7. 7p. - Publication Year :
- 2015
-
Abstract
- Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15216616
- Volume :
- 158
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Clinical Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 102464693
- Full Text :
- https://doi.org/10.1016/j.clim.2015.02.014